
Edward Ryan
Director of Global Infectious Diseases at Massachusetts General Hospital; Professor of Medicine at Harvard Medical School and Harvard T.H. Chan School of Public Health; expert in cholera, enteric infections, and tropical medicine.
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
Jun 10, 2026
NEJM Interview: Edward Ryan on factors driving continued disease and death from cholera and opportunities for progress.
1:29
1:38
1:55
2:02

Edward RyanGUEST
So the first was the recognition that vaccines should be part of a holistic plan to address cholera control.

Edward RyanGUEST
And the good news in two thousand and ten to thirteen range was that there was already a cholera vaccine that had been developed, an oral cholera vaccine, that was comprised of killed organisms that people could ingest.

Edward RyanGUEST
So the first was moving it into larger scale production and increasing the quantity of the vaccine.

Edward RyanGUEST
In about two thousand and thirteen or so, approximately five million dosages of the vaccine were available or could be made on an annual basis.
7:04
And then getting back to clean water and sanitary options, what strategies do you see that could help expand those options around the world, including for the people in the informal settlement areas that you talked about?
